NAS:CTNM (USA)
Â
Class A Common Stock
$
20.09
-0.6 (-2.9%)
11:09 PM EST
Business Description
Contineum Therapeutics Inc
NAICS : 541713
SIC : 2833
Share Class Description:
CTNM: Class A Common StockDescription
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 201.55 | |||||
Equity-to-Asset | -0.61 | |||||
Debt-to-Equity | -0.01 | |||||
Debt-to-EBITDA | -0.04 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 56.04 | |||||
9-Day RSI | 58.07 | |||||
14-Day RSI | 58.62 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 19.2 | |||||
Quick Ratio | 19.2 | |||||
Cash Ratio | 18.91 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
FCF Margin % | -37.65 | |||||
ROA % | -12.36 | |||||
ROIC % | -402.51 | |||||
ROC (Joel Greenblatt) % | -1229.71 | |||||
ROCE % | -13.12 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 7.14 | |||||
EV-to-EBIT | -24.44 | |||||
EV-to-EBITDA | -24.58 | |||||
EV-to-Revenue | 7.99 | |||||
EV-to-FCF | -21.22 | |||||
Earnings Yield (Greenblatt) % | -4.09 | |||||
FCF Yield % | -3.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CTNM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Contineum Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 50 | ||
EPS (TTM) ($) | -0.598 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 58.62 | ||
14-Day ATR ($) | 1.825898 | ||
20-Day SMA ($) | 18.151 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 13.27 - 22 | ||
Shares Outstanding (Mil) | 25.72 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Contineum Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Contineum Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Contineum Therapeutics Inc Frequently Asked Questions
What is Contineum Therapeutics Inc(CTNM)'s stock price today?
The current price of CTNM is $20.09. The 52 week high of CTNM is $22.00 and 52 week low is $13.27.
When is next earnings date of Contineum Therapeutics Inc(CTNM)?
The next earnings date of Contineum Therapeutics Inc(CTNM) is 2024-08-30 Est..
Does Contineum Therapeutics Inc(CTNM) pay dividends? If so, how much?
Contineum Therapeutics Inc(CTNM) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |